Inventor
RIZZI JAMES P
US41 patents
⚠️ This page may combine multiple inventors who share the name “RIZZI JAMES P”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
PFIZER
14 patentsUS5863949AJan 26, 1999
Arylsulfonylamino hydroxamic acid derivatives
PFIZER528 citations99
US5861510AJan 19, 1999
Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors
PFIZER536 citations98
US5223522AJun 29, 1993
Thiazolidinedione hypoglycemic agents
PFIZER77 citations96
US5120754AJun 9, 1992
Thiazolidinedione hypoglycemic agents
PFIZER55 citations96
US5061717AOct 29, 1991
Thiazolidinedione hypoglycemic agents
PFIZER59 citations96
US5994351ANov 30, 1999
Arylsulfonylamino hydroxamic acid derivatives
PFIZER15 citations82
US4914207AApr 3, 1990
Arylthiazolylimidazoles
PFIZER16 citations74
US4767743AAug 30, 1988
Peptide immunostimulants
PFIZER8 citations74
US5883131AMar 16, 1999
Cyclic sulfone derivatives
PFIZER8 citations71
US6380219B1Apr 30, 2002
Arylsulfonylamino hydroxamic acid derivatives
PFIZER2 citations63
US6147074ANov 14, 2000
Arylsulfonylamino hydroxamic acid derivatives
PFIZER2 citations63
US4963689AOct 16, 1990
Heterocyclicguanidines as 5HT3 antagonists
PFIZER3 citations63
US4452806AJun 5, 1984
Treating diabetic complications with 5-(substituted phenyl)hydantoins
PFIZER2 citations63
US6509337B1Jan 21, 2003
Arylsulfonyl Hydroxamic Acid derivatives as MMP and TNF inhibitors
PFIZER6 citations61
PELOTON THERAPEUTICS INC
11 patentsUS9908845B2Mar 6, 2018
Aryl ethers and uses thereof
PELOTON THERAPEUTICS INC16 citations92
US10597366B2Mar 24, 2020
Aryl ethers and uses thereof
PELOTON THERAPEUTICS INC4 citations83
US10144711B2Dec 4, 2018
Aryl ethers and uses thereof
PELOTON THERAPEUTICS INC8 citations83
US9969689B2May 15, 2018
Aryl ethers and uses thereof
PELOTON THERAPEUTICS INC8 citations83
US9896418B2Feb 20, 2018
Aryl ethers and uses thereof
PELOTON THERAPEUTICS INC9 citations83
US9884843B2Feb 6, 2018
Cyclic sulfone and sulfoximine analogs and uses thereof
PELOTON THERAPEUTICS INC9 citations83
USRE49948EApr 30, 2024
Aryl ethers and uses thereof
PELOTON THERAPEUTICS INC1 citations72
US10807948B2Oct 20, 2020
Aromatic compounds and uses thereof
PELOTON THERAPEUTICS INC2 citations72
US11591355B2Feb 28, 2023
CD73 inhibitors and uses thereof
PELOTON THERAPEUTICS INC2 citations59
US12331068B2Jun 17, 2025
Compositions and methods for inhibiting CD73
PELOTON THERAPEUTICS INC0 citations44
US10040767B2Aug 7, 2018
Benzimidazole derivatives and uses thereof
PELOTON THERAPEUTICS INC0 citations41
ARRAY BIOPHARMA INC
9 patentsUS7799782B2Sep 21, 2010
P38 inhibitors and methods of use thereof
ARRAY BIOPHARMA INC600 citations97
US6362216B1Mar 26, 2002
Compounds which inhibit tryptase activity
ARRAY BIOPHARMA INC29 citations92
US8044083B2Oct 25, 2011
Kinase inhibitors and methods of use thereof
ARRAY BIOPHARMA INC5 citations71
US6221914B1Apr 24, 2001
Sulfonamide bridging compounds that inhibit tryptase activity
ARRAY BIOPHARMA INC4 citations63
US9809590B2Nov 7, 2017
Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors
ARRAY BIOPHARMA INC1 citations61
US8017641B2Sep 13, 2011
P38 inhibitors and methods of use thereof
ARRAY BIOPHARMA INC1 citations60
US8039639B2Oct 18, 2011
Kinase inhibitors and methods of use thereof
ARRAY BIOPHARMA INC4 citations58
US8026233B2Sep 27, 2011
P38 inhibitors and methods of use thereof
ARRAY BIOPHARMA INC2 citations51
US10669269B2Jun 2, 2020
Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors
ARRAY BIOPHARMA INC0 citations49
AMGEN INC
3 patentsUS6180643B1Jan 30, 2001
Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
AMGEN INC49 citations95
US6605634B2Aug 12, 2003
Aryl and heteroaryl substituted fused pyrrole anti-inflammatory agents
AMGEN INC33 citations91
US6440973B1Aug 27, 2002
Aryl and heteroaryl substituted fused pyrrole antiinflammatory agents
AMGEN INC36 citations91
BOYS MARK LAURENCE
2 patentsUS9174981B2Nov 3, 2015
Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors
BOYS MARK LAURENCE3 citations58
US8841455B2Sep 23, 2014
Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as cFMS inhibitors
BOYS MARK LAURENCE1 citations46